Wealth Enhancement Trust Services’s Viridian Therapeutics VRDN Stock Holding History

Wealth Enhancement Trust Services’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367	Buy	+20	New	+$322	﹤0.01%	1288

Other funds holding VRDN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Wealth Enhancement Trust Services's VRDN Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 20 shares worth $367. The stake represents ﹤0.01% of the portfolio and ranks #1288 among its holdings.

103 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Wealth Enhancement Trust Services held 20 shares of Viridian Therapeutics worth $367 as of Q2 2026.
Viridian Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Viridian Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1288 holding.
103 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.